STERIS plc Stock News

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some o

STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.

DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 fourth q

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.

The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt gr

The heavy selling pressure might have exhausted for Steris (STE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r

Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.

Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.

The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat

Steris (STE) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.02 per share a year ago.

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for som

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.